Sandoz利妥昔单抗生物类似药治疗活动性类风湿关节炎的52周随机对照ASSIST-RA试验结果
ASSIST-RA研究比较Sandoz利妥昔单抗(SDZ-RTX)与参照利妥昔单抗(Ref-RTX)联合甲氨蝶呤治疗活动性类风湿关节炎,至第52周时两组在外周B细胞浓度、疗效、安全性和免疫原性方面均相似。312例随机患者中260例完成第52周治疗,SDZ-RTX与Ref-RTX的DAS28、ACR20/50/70、CDAI、SDAI和HAQ-DI变化相近,不良事件频率、类型和严重程度及抗药抗体发生率低且短暂亦相似。
要点
- SDZ-RTX与Ref-RTX在外周B细胞浓度随时间变化上相似。
- 至第52周,SDZ-RTX与Ref-RTX的DAS28、ACR20/50/70、CDAI、SDAI和HAQ-DI疗效指标相似。
- 两组不良事件频率、类型和严重程度及抗药抗体发生率低且短暂均相似。
核心结论
- SDZ-RTX在52周内表现出与Ref-RTX相似的B细胞浓度、疗效、安全性和免疫原性。
研究设计与样本
- ASSIST-RA为随机对照试验,患者随机接受SDZ-RTX或Ref-RTX联合甲氨蝶呤治疗,主要终点在第24周分析。
主要发现
- 312例随机患者中260例完成至第52周治疗。
- SDZ-RTX在外周B细胞浓度随时间变化上与Ref-RTX相似。
- SDZ-RTX在DAS28、ACR20/50/70、CDAI、SDAI和HAQ-DI上疗效与Ref-RTX相似至第52周。
- SDZ-RTX不良事件频率、类型和严重程度与Ref-RTX相似,且与已知Ref-RTX安全性特征一致。
- 抗药抗体发生率低且短暂,各治疗组相似。
临床怎么用
- SDZ-RTX可作为Ref-RTX的生物类似药用于活动性类风湿关节炎联合甲氨蝶呤治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This report provides data for the extent of B cell depletion and recovery, efficacy, safety and immunogenicity of Sandoz rituximab (SDZ-RTX; GP2013; Rixathon®) compared with reference rituximab (Ref-RTX) up to week 52 of the ASSIST-RA study. METHODS: Patients were randomized to SDZ-RTX or Ref-RTX in combination with methotrexate according to the RTX label. The primary endpoint was analysed at week 24. Responders (28-joint DAS [DAS28] decrease from baseline >1.2) at week 24 with residual disease activity (DAS28 ≥2.6) were eligible for a second treatment course between week 24 and 52. Endpoints after week 24 included change from baseline in peripheral B cells, DAS28, ACR 20% response rate (ACR20), Clinical and Simplified Disease Activity Indexes (CDAI, SDAI) and HAQ disability index (HAQ-DI). Safety and immunogenicity were assessed by the incidence of adverse events and antidrug antibodies. RESULTS: Primary and secondary endpoints up to week 24 were met. Overall, 260/312 randomized patients completed treatment up to week 52. SDZ-RTX resulted in B cell concentrations over time similar to Ref-RTX. The efficacy of SDZ-RTX was similar to Ref-RTX up to week 52, as measured by DAS28, ACR20/50/70, CDAI, SDAI and HAQ-DI. Safety of SDZ-RTX was similar to Ref-RTX regarding frequency, type and severity of adverse events, which were consistent with the known Ref-RTX safety profile. The incidence of antidrug antibodies was low and transient similarly across treatment groups. CONCLUSION: SDZ-RTX demonstrated similar B cell concentrations over time, efficacy, safety and immunogenicity to Ref-RTX over 52 weeks of the ASSIST-RA study.
引用
- Smolen JS, Cohen SB, Tony HP, et al. Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial. Rheumatology (Oxford). 2021. PMID: 32699904. doi:10.1093/rheumatology/keaa234
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。